Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases.

Abstract

Due to the low incidence of rare EGFR mutation, its response to EGFR-TKI has not been fully investigated. L747P is a rare EGFR mutation in EGFR exon 19. Previous case reports showed that patients with EGFR L747P mutation responded to afatinib treatment. However, we encountered a patient with EGFR L747P who was resistant to afatinib but responded to dacomitinib. It is the first case report of the effective application of dacomitinib in a patient with L747P mutation and BMS, and the efficacy of BMS achieved PR.

• Authors: Yibin Li, Weixi Guo, Bin Jiang, Chengkun Han, Feng Ye, Jingxun Wu
• Journal: Frontiers in oncology (Front Oncol) Vol. 12 Pg. 863771 ( 2022) ISSN: 2234-943X [Print] Switzerland
• PMID: 36016627 (Publication Type: Case Reports)
• Copyright: Copyright © 2022 Li, Guo, Jiang, Han, Ye and Wu.